COVID-19 Ongoing Studies

Subject to their eligibility and consent, we are aiming for every patient with COVID-19 disease who is admitted to our hospitals to be given the opportunity to be part of one of the research trials or studies that we are running at Imperial. 

Summary of recruitment to our key studies:

Study Recruitment to date

RECOVERY


86

REMAP-CAP 24
C-19-ACS 70
Novel Coronavirus Observational Study (ISARIC) Tier 0: 1364
Tier 2: 77
Imperial Health Knowledge Bank 731
BioAID 871
DIAMONDS 169
REACT-2 275
PAN-COVID 162
GenoMMIC 30
COVAC1 (Imperial Vaccine Study) 120

Find out more about ongoing studies, including recruitment over time, by following links below.

INTERVENTIONAL STUDIES

RECAP: Remote COVID-19 Assessment in Primary Care

RECOVERY: Randomised Evaluation of COVID-19 Therapy

REMAP-CAP: A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia

C19-ACS: Preventing Cardiac Complications of COVID-19 Disease with Early Acute Coronary Syndrome Therapy

Gilead: Safety & Antiviral Activity of Remdesivir for COVID-19

COVACTA: A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

COV001: A Study of a Candidate COVID-19 Vaccine


OBSERVATIONAL STUDIES

ISARIC: Coronavirus Clinical Characterisation Consortium

Imperial Health Knowledge Bank

BioAID: Bioresource for Adult Infectious Disease

OnCovid: natural history and outcomes of cancer patients during the COVID19 epidemic

DIAMONDS: Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis

PanSurge PREDICT: a global effort to collect data on all surgical patients presenting to hospital during the COVID19 pandemic

PAN-COVID: Pregnancy and Neonatal Outcomes in COVID-19

C19-RISP: The effect of Covid19 on Renal and Immuno-Suppressed Patients